

14th August 2019

The Secretary Bombay Stock Exchange Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai 400 001 The Secretary The National Stock Exchange of India Limited Exchange Plaza, 5th Floor Plot No. C/1, G Block Bandra-Kurla Complex Bandra East, Mumbai 400 050

Disclosure of Related Party Transactions pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)

Dear Sirs

The unaudited financial results of the Company for the quarter and half year ended 30th June 2019 were approved by the Board of Directors of the Company at its meeting held on 29th July 2019 and published on 31st July 2019. Pursuant to Regulation 23(9) of Listing Regulations, please find enclosed the disclosures of related party transactions for the half year ended 30th June 2019 in the format specified in the applicable accounting standards.

Kindly take the above information on record.

Thanking you,

Yours faithfully For SANOFI INDIA LIMITED GIRISH TEKCHANDANI COMPANY SECRETARY

Related Party Disclosures

- i. Parties where control exists:
 - a) Sanofi S.A. France, ultimate holding Company
 - b) Hoechst GmbH, Germany, holding Company

ii. Other related parties in Sanofi Group where common control exists and with whom transactions have taken place during the year.

(₹ in Million)

Sanofi-Aventis Singapore Pte. Limited Francopia S.A.R.L. Sanofi-Aventis Deutschland GmbH Sanofi-Aventis Groupe S.A. Sanofi Lanka Limited Sanofi-aventis U.S.Inc. Sanofi Chimie S.A Sanofi Pasteur India Private Limited Sanofi-Synthelabo (India) Private Limited Sanofi Winthrop Industrie S.A. Sanofi-Aventis Pakistan Limited Sanofi-Aventis Recherche et Développement S.A. Sanofi-Aventis Spa Shantha Biotechnics Private Limited Sanofi India Limited Provident Fund

- iii. Key management personnel of the Company for the year

 Mr. Rajaram Narayanan
 - Managing Director

 Mr. Ashwani Sood
 - Whole Time Director (till the closure of business hours of May 31, 2019)
 - Mr. Charles Billard - Whole Time Director and CFO
 - Mr. Girish Tekchandani Company Secretary

iv. Non-Executive Directors

- Mr. Thomas Rouckout
- Mr. Cyril Grandchamp-Desraux
- Dr. Shailesh Ayyangar

v. Independent Directors

- Mr. Aditya Narayan Mr. Rangaswamy R. Iyer
- Mrs. Usha Thorat

vi. Transactions during the year

Particulars	June 30, 2019
Ultimate Holding Company	
Dividend paid	*
Holding Company	
Dividend paid	918
Other related Parties	
Sale of Products	
Sanofi-Aventis Singapore Pte. Limited	3,835
Others Total	303 4,138
	4,250
Purchase of Raw Materials and Traded Goods	
Sanofi-Aventis Singapore Pte. Limited Others	3,480
Total	3,488
Expenses recharged to other companies	*
Sanofi-Synthelabo (India) Private Limited	÷
Sale of Services	
Sanofi-Synthelabo (India) Private Limited	592
Sanofi Pasteur India Private Limited	96 69
Sanofi Winthrop Industrie S.A. Others	34
Total	791
Rent Income Sanofi-Synthelabo (India) Private Limited	4
Sanon-Synchelabo (India) Frivate Linited	
Loans repaid	
Sanofi Pasteur India Private Limited	500
Mr. Ashwani Sood Total	500
Iocal	500
Interest income on loans	
Shantha Biotechnics Private Limited	210
Sanofi Pasteur India Private Limited	5
Total	215



Particulars	June 30, 2019
Expenses recharged by other companies	
Sanofi-Synthelabo (India) Private Limited Sanofi Winthroo Industrie S.A.	28 10
Sanofi-Aventis Groupe S.A.	6
Others Total	5
Total	49
Contribution to In-house Trust for Post Employment Benefits - Provident Fund Sanofi India Limited Provident Fund #	138
	150
Payment towards Intangibles under development Sanofi-Synthelabo (India) Private Limited	7
Key Management Personnel Remuneration	
Remuneration	
Mr. Rajaram Narayanan	19
Mr. Ashwani Sood Mr. Charles Billard	5
Mr. Girish Tekchandani	6
Total	39
Share based benefit	
Mr. Rajaram Narayanan	6
Mr. Charles Billard	1
Total	7
Sitting Fees to Independent Directors	
Mr. Aditya Narayan	*
Mr. Rangaswamy R. Iyer	*
Ms. Usha Thorat	*
Total	1
Commission to Independent Directors	
Mr. Aditya Narayan	2
Mr. Rangaswamy R. Iyer	1
Ms. Usha Thorat Mr. A. K. R. Nedungadi (upto January 15, 2018)	1
Total	3

* denotes figure less than a million

Including contribution by employees.


Terms and conditions of transactions with related parties

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. For the year six month ended June 30, 2019, the Company has not recorded any impairment of receivables relating to amounts owed by related parties. This assessment is undertaken each financial year through examining the financial position of the related party and the market in which the related party operates.

(₹ in Million)

vii. Outstanding as at June 30, 2019

Particulars	June 30, 2019
Other related Parties	
Trade Receivables Sanofi-Aventis Singapore Pte. Limited Sanofi-Synthelabo (India) Private Limited Others Total	1,193 109 218 1,520
Trade Payables Sanofi-Aventis Singapore Pte. Limited Sanofi-Synthelabo (India) Private Limited Others Total	1,148 158 7 1,313
Others Payables Sanofi-Aventis Singapore Pte. Limited Total	36 36
Loans receivable Shantha Biotechnics Private Limited# Mr. Ashwani Sood * Total	4,450 * 4,450



#Loans given to Shantha Biotechnics Private Limited at the rate of interest of 9.5% p.a. Maximum balance outstanding during the year ₹ 4,450 Million The said loans have been proposed to be utilized by Shantha Biotechnics Private Limited for business purpose. The Loan have been given against corporate guarantee by Sanofi S.A. (Ultimate Holding Company). The Maturity Date of same is April 15, 2020.

* Given as per the Company's policies for employees.